Shagrani M, Burkholder J, Broering D, Abouelhoda M, Faquih T, El-Kalioby M, Subhani S N, Goljan E, Albar R, Monies D, Mazhar N, AlAbdulaziz B S, Abdelrahman K A, Altassan N, Alkuraya F S
Organ Transplant Centre, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Department of Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Clin Genet. 2017 Jul;92(1):52-61. doi: 10.1111/cge.12959. Epub 2017 Mar 17.
Advanced cholestatic liver disease is a leading referral to pediatric liver transplant centers. Recent advances in the genetic classification of this group of disorders promise a highly personalized management although the genetic heterogeneity also poses a diagnostic challenge. Using a next-generation sequencing-based multi-gene panel, we performed retrospective analysis of 98 pediatric patients who presented with advanced cholestatic liver disease. A likely causal mutation was identified in the majority (61%), spanning many genes including ones that have only rarely been reported to cause cholestatic liver disease, e.g. TJP2 and VIPAS39. We find no evidence to support mono-allelic phenotypic expression in the carrier parents despite the severe nature of the respective mutations, and no evidence of oligogenicity. The high-carrier frequency of the founder mutations identified in our cohort (1 in 87) suggests a minimum incidence of 1:7246, an alarmingly high disease burden that calls for the primary prevention through carrier screening.
晚期胆汁淤积性肝病是儿科肝移植中心的主要转诊疾病。尽管基因异质性也带来了诊断挑战,但这组疾病在基因分类方面的最新进展有望实现高度个性化的管理。我们使用基于下一代测序的多基因检测板,对98例患有晚期胆汁淤积性肝病的儿科患者进行了回顾性分析。在大多数患者(61%)中发现了可能的致病突变,涉及许多基因,包括一些很少被报道可导致胆汁淤积性肝病的基因,如TJP2和VIPAS39。尽管各自的突变性质严重,但我们没有发现证据支持携带者父母中存在单等位基因表型表达,也没有发现寡基因性的证据。在我们的队列中确定的奠基者突变的高携带者频率(87人中1人)表明最低发病率为1:7246,这是一个惊人的高疾病负担,需要通过携带者筛查进行一级预防。